

Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists

Margaret Ottaviano (*), ^{1,2} Marcello Curvietto, ³ Pasquale Rescigno, ⁴ Marianna Tortora, ⁵ Giovannella Palmieri, ⁵ Diana Giannarelli, ⁶ Michele Aieta, ⁷ Pasquale Assalone, ⁸ Laura Attademo, ⁹ Antonio Avallone, ¹⁰ Francesco Bloise, ¹¹ Davide Bosso, ¹² Valentina Borzillo, ¹³ Giuseppe Buono, ¹⁴ Giuseppe Calderoni, ¹⁵ Francesca Caputo, ¹⁶ Giacomo Cartenì, ¹⁷ Diletta Cavallero, ¹¹ Alessia Cavo, ¹⁸ Fortunato Ciardiello, ¹⁹ Raffaele Conca, ⁷ Vincenza Conteduca, ²⁰ Stefano De Falco, ²¹ Marco De Felice, ^{19,22} Michelino De Laurentiis, ²³ Pietro De Placido, ²⁴ Sabino De Placido, ^{5,24} Irene De Santo, ²⁵ Alfonso De Stefano, ¹⁰ Carminia Maria Della Corte, ¹⁹ Rossella Di Franco, ¹³ Vincenzo Di Lauro, ^{23,24} Antonietta Fabbrocini, ¹² Piera Federico, ¹² Lucia Festino, ³ Pasqualina Giordano, ¹² Mario Giuliano, ^{5,24} Cesare Gridelli, ²⁶ Antonio Maria Grimaldi, ³ Michela Lia, ²⁷ Antonella Lucia Marretta, ²⁴ Valentina Massa, ¹¹ Alessia Mennitto, ²⁸ Sara Merler, ²⁹ Valeria Merz ⁶, ³⁰ Carlo Messina, ³⁰ Marco Messina, ³¹ Monica Milano, ²⁸ Alessandro Marco Minisini, ³² Vincenzo Montesarchio, ¹⁶ Alessandro Morabito ⁶, ³³ Floriana Morgillo, ¹⁹ Brigitta Mucci, ²⁴ Lucia Nappi, ³⁴ Fabiana Napolitano, ²⁴ Immacolata Paciolla, ³⁵ Martina Pagliuca, ²⁴ Giuseppe Palmieri, ³⁶ Sara Parola, ²⁴ Stefano Pepe, ³⁷ Angelica Petrillo ⁶, ^{12,19} Francovito Piantedosi, ³⁸ Luisa Piccin, ³⁹ Fernanda Picozzi, ²⁴ Erica Pietroluongo, ²⁴ Sandro Pignata, ⁹ Veronica Prati, ⁴⁰ Vittorio Riccio, ²⁴ Mario Rosanova, ¹² Alice Rossi, ²⁹ Anna Russo, ⁴¹ Massimiliano Salati, ⁴² Giuseppe Santabarbara, ²⁶ Andrea Sbrana, ¹¹ Ester Simeone, ³ Antonia Silvestri, ¹² Massimiliano Spada, ⁴³ Paolo Tarantino, ⁴⁴ Paola Taveggia, ¹⁸ Federica Tomei, ⁸ Tortora Vincenzo, ^{24,37} Dario Trapani, ⁴⁴ Claudia Trojanello, ³ Vito Vanella, ³ Sabrina Vari, ⁴⁵ Jole Ventriglia, ⁴⁶ Maria Grazia Vitale, ^{3,32} Fabiana Vitiello, ³⁸ C

To cite: Ottaviano M,

Curvietto M, Rescigno P, *et al.* Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. *Journal for ImmunoTherapy of Cancer* 2020;**8**:e001154. doi:10.1136/jitc-2020-001154

 Additional material is published online only. To view, please visit the journal online (http://dx.doi.org/10.1136/jitc-2020-001154).

Accepted 08 August 2020



© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Paolo Antonio Ascierto; paolo.ascierto@gmail.com

ABSTRACT

Background The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania region.

Methods This survey (25 questions), promoted by the young section of SCITO (Società Campana di ImmunoTerapia Oncologica) Group, was circulated among Italian young oncologists practicing in regions variously affected by the pandemic: high (group 1), medium (group 2) and low (group 3) prevalence of SARS-CoV-2–positive patients. For Campania region, the physician responders were split into those working in cancer centers (CC), university hospitals (UH) and general hospitals (GH). Percentages of agreement, among High (H) versus Medium (M) and versus Low (L) group for Italy and among CC, UH and GH for Campania region, were compared by using Fisher's exact tests for dichotomous answers and γ^2 test for trends relative to the questions with 3 or more options. Results This is the first Italian study to investigate the COVID-19 impact on cancer immunotherapy, unique in its type and very clear in the results. The COVID-19 pandemic seemed not to affect the standard practice in the prescription and delivery of ICIs in Italy. Telemedicine was widely used. There was high consensus to interrupt immunotherapy in SARS-CoV-2-positive patients and to adopt ICIs with longer schedule interval. The majority of the responders tended not to delay the start of ICIs; there were no changes in supportive treatments, but some of the physicians opted for delaying surgeries (if part of patients' planned treatment approach). The results from responders in Campania did not differ significantly from the national ones.

Conclusion Our study highlights the efforts of Italian oncologists to maintain high standards of care for CPs

BMJ

Open access

treated with ICIs, regardless the regional prevalence of COVID-19, suggesting the adoption of similar solutions. Research on patients treated with ICIs and experiencing COVID-19 will clarify the safety profile to continue the treatments, thus informing on the most appropriate clinical conducts.

INTRODUCTION

The world is currently in the midst of the largest medical emergency since the influenza pandemic of 1918, due to the novel respiratory syndrome COVID-19 ('coronavirus disease 2019') pandemic, caused by the coronavirus SARS-CoV-2, with over 3,767,744 diagnosed cases and 259,593 deaths across 210 countries around the world, as of May 8, 2020.¹ The outbreak of COVID-19, declared as a pandemic by WHO on March 11, 2020,² has overwhelmed the public health systems worldwide. Originated in China, and then moved to Europe and Italy, the scenario of virus rapid spread has resulted in high number of cases and relative deaths,² and prompted the implementation of public health measures of containment to prevent the disease transmission, protect healthcare workers, and increase healthcare-system capacity, especially intensive care units and COVID-19 dedicated areas.³ As widely recognized, the risk and the severity of COVID-19 infection seem to be associated with older age and pre-existing comorbidities, such as diabetes, chronic cardiopulmonary disease and immune depression,⁴ thus cancer patients (CPs) and cancer survivors could represent additional high-risk categories.⁵ Considering the prevalence of cancer worldwide and the current COVID-19 pandemic, there is an urgent need to depict the effects of this new infection on cancer treatments, to ensure protection of one possible vulnerable population of patients. In response to the lack of reliable data on CPs and navigating in a plethora of assumptions, opinions and perspectives that are not evidence based, several international collaborations have been developed, including the Research Collaborative Registry for Hematologic Malignancy (led by the American Society of Hematology), the TERAVOLT group study ("thoracic cancers international COVID-19 collaboration", led by the Italian National Cancer Institute), the UK Coronavirus cancer-monitoring project, the American Association of Clinical Oncology Survey on COVID-19 in Oncology Registry, the web-based CCC19 Registry (the COVID-19 and Cancer Consortium) and the European Society of Medical Oncology ESMO-CoCARE registry (online supplemental appendix table 1).⁶ However, to date, the CP populations described in several reports lack extensive descriptions of individuals receiving anticancer immune checkpoint inhibitors (ICIs),⁷ which represent the standard option in several solid tumors such as melanoma and non-melanoma skin tumors, lung cancer, renal carcinoma, urothelial cancers, head and neck carcinoma, and more recently, breast cancers.⁸ Therefore, with the aim to depict the management of CPs with solid tumors undergoing or candidate for ICIs during the COVID-19 pandemic, a survey promoted by the young section of SCITO (Società Campana di

ImmunoTerapia Oncologica),⁹ which includes certified oncologists under 45 years old, was circulated among Italian young oncologists.

METHODS

The survey was generated by the young section of the cooperative network SCITO and sent by email, from April 10 to May 8, 2020, to Italian young oncologists with recognized experience in anticancer immunotherapy, who were assigned to three group of regions, according to the national COVID-19 epidemiological data of May 8, 2020 (data cutoff): group 1, high (H) prevalence regions with more than 10,000 positive patients; group 2, medium (M) prevalence regions with positive patients less than 10,000 and more than 4000; group 3, low (L) prevalence regions with less than 4000 positive patients (figure 1). The survey consisted of 25 questions, which were organized in three sections. The first section (from question number 1 to question number 8) assessed the routine triaging-screening procedures for SARS-CoV-2 in CPs undergoing or candidate for ICIs, the COVID-19 containment measures adopted and the positivity for COVID-19 in CPs while on immunotherapies. At the time of data cut-off, according to the indications of the Italian National Institute of Health, triage of oncological patients included vital signs monitoring before entering the oncologic clinic (body temperature, SpO₉, respiratory rate) and questioning patients on the presence of suspicious symptoms during the 15 days before the visit and possible contacts with subjects affected by COVID-19 or coming from high-risk areas. In case of suspicious symptoms or possible contacts, the triage procedure was followed by preventive isolation and diagnostic work-up according to the regional specific indications. The second section (from question number 9 to question number 20) assessed the treatment modality adaptations for medical and surgical treatments provided to CPs undergoing or candidate for ICIs during the COVID-19 pandemic, as well as the adaptations of supportive therapies. The third and last section (from question number 21 to question number 25) assessed the physicians' characteristics such as age, professional position, affiliation, geographical distribution and field of interest. A complete original version of the survey is provided in online supplemental appendix. The answers were collected and reviewed by two reference members of SCITO young section (MO and MC). The survey responses were analyzed blinded for the submitting author's identity. The percentage of consensus among the H, M and L COVID-19 prevalence regions (CPR) and among the cancer centers (CC), university hospitals (UH) and general hospitals (GH) of Campania Region were compared by using Fisher's exact tests for dichotomous answers and $\chi^2 \log$ test for the questions with three or more options. All tests were two sided. Significance was set at p value <0.05 (only the p value for significant results has been shown). The data were analyzed using GraphPad Prism V.8.3.0 (GraphPad Software, San Diego, CA, USA). The epidemiology data about the COVID-19 prevalence and mortality were extracted from the Italian Health Minister website (http://www.salute.




Figure 1 Epidemiology of COVID-19. Epidemic graphic maps of Europe (A), Italy (B) and Campania (C) at the end time of circulation of the survey among young Italian oncologists. The maps report the prevalence of COVID-19–positive patients corresponding to the last day of the survey dates interval (May 8). The tables report the survey dates, the prevalence of COVID-19–positive patients and COVID-19–related deaths at the time of the survey. The red dots mark the geographic areas of the physician responders.

gov.it/portale/nuovocoronavirus/); the data-wrapper software (https://www.datawrapper.de) was used to create the epidemic graph maps.

Table 1 Characteristics of physicians who responded to						
the survey (survey section 3)						
	Total number and % Italy	Total number and % Campania				
	75 responders	38 responders				
Professional position						
Specialists	49 (65.3%)	26 (68.4%)				
Trainees	26 (34.7%)	12 (31.6%)				
Age						
<35 years old	43 (57.3%)	20 (52.6%)				
>35 years old	32 (42.7%)	18 (47.4%)				
Affiliation						
Cancer center	23 (30.7%)	10 (26.4%)				
University hospital	24 (32%)	12 (31.5%)				
General hospital	28 (37.3%)	16 (42.1%)				
Field of interest						
Thoracic cancers	27 (36%)	15 (39.4%)				
Urogenital cancers	17 (22.7%)	8 (21%)				
Melanoma	13 (17.3%)	8 (21%)				
Others	18 (24%)	7 (18.3%)				

RESULTS

Seventy-five young oncologists, daily involved in the management of CPs treated with ICIs, responded to the survey, with a 100% survey completion rate. Seventeen physicians belonged to H CPR, fifty-one and seven physicians to, respectively, M and L CPR. All the participants were medical oncologists, with the exception of a radiation oncologist. For the Campania Region analysis, 38 oncologists were included, divided into 10 for CC, 12 for UH and 16 for GH. To simplify consultation and interpretation of results, tables 1 and 2 show physicians' characteristics and geographical collocation (third survey's section); tables 3 and 4 show answers to multiple-choice questions of first and second sections; tables 5 and 6 show answers to multiple-choice questions of first and second sections relatively to Campania region's oncologists. Figure 1 reports the epidemic graph maps of the COVID-19 pandemic at the time of the last collection of survey responses (May 8) for Europe, Italy and Campania Region, respectively.

Italian experience: differences and similarities among high (H), medium (M) and low (L) COVID-19 prevalence regions (CPR)

CPs were preferentially triaged for COVID-19–related symptoms on the day before the hospital appointment by telephonic consultation and on the day of clinic appointment through physical examinations in dedicated areas in H and M CPR (H=82.4%; M=58.8%), while in the L

Table 2 Geographical distribution and affiliations of physicians who responses Name of institution Institution	City	Region	Туре	
A.O. Moscati	Avellino	Campania	GH	
A.O. Dei Colli Ospedale Monaldi	Naples	Campania	GH	
A.O. Ordine Mauriziano	Torino	Piemonte	GH	
A.O.U. degli studi della Campania "Luigi Vanvitelli"	Naples	Campania	UH	
A.O.U. degli studi di Napoli Federico II	Naples	Campania	UH	
A.O.U. di Modena	Modena	Emilia Romagna	UH	
A.O.U. di Pisa	Pisa	Toscana	UH	
A.O.U. San Giovanni di Dio Ruggi d'Aragona	Salerno	Campania	UH	
A.O.U.I. di Verona	Verona	Veneto	UH	
A.S.L. Caserta Presidio San Felice a Cancello	Caserta	Campania	GH	
A.S.L. Caserta Presidio Sessa Aurunca Ospedale San Rocco	Caserta	Campania	GH	
A.S.L. CN2 Alba-Bra	Verduno	Piemonte	GH	
A.S.L. Napoli 1 Centro Ospedale del Mare	Naples	Campania	GH	
Azienda Sanitaria Universitaria Integrata del Friuli Centrale	Udine	Friuli Venezia Giulia	UH	
Fondazione IRCCS Istituto Nazionale dei Tumori	Milan	Lombardia	CC	
Fondazione Istituto G. Giglio	Cefalù	Sicilia	GH	
Gemelli Molise s.p.a	Campobasso	Molise	CC	
IRCCS "Giovanni Paolo II"	Bari	Puglia	CC	
IRCCS CROB	Rionero in Vulture	Basilicata	CC	
Istituto Europeo di Oncologia–IEO	Milan	Lombardia	CC	
Istituto Nazionale dei Tumori "Regina Elena"–IRCCS	Rome	Lazio	CC	
Istituto Nazionale dei Tumori Fondazione G. Pascale–IRCCS	Naples	Campania	CC	
Istituto Oncologico del Veneto IRCCS-IOV	Padua	Veneto	CC	
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS	Meldola	Emilia Romagna	CC	
Ospedale Della Murgia "F. Perinei"	Altamura	Puglia	GH	
Ospedale Fatabenefratelli	Benevento	Campania	GH	
Ospedale S. Ottone Frangipane	Ariano Irpino	Campania	GH	
Ospedale Sant'Anna e San Sebastiano	Caserta	Campania	GH	
Ospedale Santa Chiara	Trento	Trentino Alto Adige	GH	
Ospedale SS. Antonio e Biagio e Cesare Arrigo	Alessandria	Piemonte	GH	
Ospedale Veneziale	Isernia	Molise	GH	
Ospedale Villa Scassi, A.S.L. 3 Genova	Genoa	Liguria	GH	
Ospedali Riuniti Villa Sofia Cervello	Palermo	Sicilia	GH	
Università degli studi di Verona, sede Borgo Roma	Verona	Veneto	UH	

CC, cancer center; GH, general hospital; UH, university hospital.

CPR, 57.1% of responders clinically assessed CPs directly in-person on the day of clinic appointment without any previous telephonic triage (p=0.03). Despite these differences, for patients suspected of COVID-19, there was high consensus on precautionary ICI interruptions and resuming the treatment after a SARS-CoV-2 negative result; only 4% of the responders reported to consider continuing ongoing ICIs in possibly symptomatic patients, thus avoiding treatment delays. Moreover, for clinically suspected cases, 11.8% of H, 35.3% of M and 28.6% of L CPR responders did not perform any additional diagnostic work-up, whereas for the remaining physicians, there was no consensus on the best diagnostic algorithm to follow. The preferred management option was immediate ICI interruption, then perform thorax CT scan even in the absence of severe respiratory symptoms and order blood test including complete blood count (CBC), lactate dehydrogenase, high-sensitivity C reactive protein, interleukin-6 and D-dimer (H=11.8%, M=15.7%, L=14.3%). Due to the inclusion of oncologists working

Table 3 Answers to multiple choice	All, n (%) H CPR, n (%) M CPR, n (%) L CPR,				
Questions	Multiple-choice responses	N=75	N=17	N=51	N=7
1. How do you triage your (CP-ICI) patients for	By telephone the day before the appointment	13 (17.3)	1 (5.9)	12 (23.5)	0 (0)
SARS-CoV-2?	 Dytaiophone the day bolie the appointment Outside the hospital the same day of the clinic appointment 	15 (20)	2 (11.8)	9 (17.6)	4 (57.1)
	□ By telephone the day before the appointment and outside the clinic the day of the appointment	47 (62.7)	14 (82.4)	30 (58.8)	3 (42.9)
2. Who among CP-ICI patients do you preferentially use telemedicine?	Patients in follow-up after finishing ICI adjuvant treatment	7 (9.3)	2 (11.8)	5 (9.8)	0 (0)
	Patients in follow-up who achieve complete response	3 (4)	2 (11.8)	1 (2)	0 (0)
	□ Both	57 (76)	11 (64.7)	40 (78.4)	6 (85.7)
	\square None of the above, I am not using telemedicine	8 (10.7)	2 (11.8)	5 (9.8)	1 (14.3)
3. How do you manage the new patients with	Delay ICI start for COVID-19 in all patients	0 (0)	0 (0)	0 (0)	0 (0)
cancer who need to start ICIs for metastatic disease?	Triage screening for COVID-19 risk factors	69 (92)	16 (94.1)	46 (90.2)	7 (100)
	□ Both	2 (2.7)	0 (0)	2 (3.9)	0 (0)
	□ None of the above	4 (5.3)	1 (5.9)	3 (5.9)	0 (0)
4. How do you manage the new patients with	Delay ICI start for COVID-19 in all patients	2 (2.7)	1 (5.9)	1 (2)	0 (0)
cancer who need to start ICIs for adjuvant purpose?	Triage screening for COVID-19 risk factors	60 (0)	15 (88.2)	41 (80.4)	4 (57.1)
	□ Both	7 (9.3)	0 (0)	5 (9.8)	2 (28.6)
	□ None of the above	6 (8)	1 (5.)	4 (7.8)	1 (14.3)
5. Do you have any CP-ICI who tested positive for	□ Yes	21 (28)	5 (29.4)	16 (31.4)	0 (0)
SARS-CoV-2?	□ No	54 (72)	12 (70.6)	35 (68.6)	7 (100)
6. If yes, how many?	□ <10	24 (96)	6 (100)	18 (94.7)	0 (0)
	□ 10–20	1 (4)	0 (0)	1 (5.3)	0 (0)
	□ 20–50	0 (0)	0 (0)	0 (0)	0 (0)
	□ 50–100	0 (0)	0 (0)	0 (0)	0 (0)
7. If yes, the most frequent CP-ICI SARS-CoV-2	Urogenital cancers	5 (20)	2 (33.3)	3 (16)	0 (0)
positive are affected by?	Thoracic cancers	14 (56)	2 (33.3)	12 (63)	0 (0)
	□ Melanoma	5 (20)	1 (16.6)	4 (21)	0 (0)
	□ Head and neck cancers	0 (0)	0 (0)	0 (0)	0 (0)
	□ Other	1 (4)	1 (16.6)	0 (0)	0 (0)
8. How do you manage CP-ICI showing suspicious symptoms for COVID-19? (more than 1	1. Order the SARS-CoV-2 test and continue with the ICIs avoiding delays	3 (4)	1 (5.9)	2 (3.9)	0 (0)
option allowed)	2. Suspend the ICIs while waiting for the test results	22 (29.3)	2 (11.8)	18 (35.3)	2 (28.6)
	3. Ask for Rx thorax even in the absence of severe respiratory symptoms	3 (4)	1 (5.9)	2 (3.9)	0 (0)
	4. Ask for thorax CT scan even in the absence of severe respiratory symptoms	4 (5.2)	1 (5.9)	2 (3.9)	1 (14.3)
	5. Ask for blood test including: CBC, lactate dehydrogenase, high-sensitivity C reactive protein, interleukin-6, D-dimer	1 (1.3)	1 (5.9)	0 (0)	0 (0)
	6. 2+5	7 (9.3)	2 (11.8)	3 (5.9)	2 (28.6)
	7.2+3	7 (9.3)	1 (5.9)	6 (11.8)	0 (0)
	8. 2+3+5	10 (13.3)	5 (29.4)	5 (9.8)	0 (0)
	9. 2+3+4	1 (1.3)	0 (0)	1 (2)	0 (0)
	10. 2+4	7 (9.3)	1 (5.9)	5 (9.8)	1 (14.3)
	11. 2+4+5	11 (14.7)	2 (11.8)	8 (15.7)	1 (14.3)

Table 3 Answers to multiple choice questions of survey section 1

H CPR: high (H) prevalence regions with more than 10,000 positive patients, M CPR: medium (M) prevalence regions with positive patients less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 4000, L CPR: low (L) prevalence regions with less than 4000, L CPR: low (L)

regions with less than 4000 positive patients. CBC, complete blood count; CP, cancer patient; CP-ICI, cancer patients undergoing or candidate for immune checkpoint inhibitor; ICI, immune checkpoint inhibitor; N, number.

in different contexts such as CC, UH and GH, including the ones hosting COVID-19 units, CPs treated with ICIs were predominantly seen in non "COVID-19 free" institutions (H=64.7%, M=58.8%, L=71.4%). As expected, telemedicine was largely implemented, both for patients in follow-up after completing ICI adjuvant treatment or achieving ICI complete response; only 11.8%, 9.8% and 14.3% of responders in H, M and L CPR used a different approach. High percentage of responders (H=88.2%, M=80.4%, L=57.1%) stated to screen all new CPs for

		All, n (%)	H CPR, n (%)	M CPR, n (%)	L CPR, n (%)
Questions	Multiple-choice responses	N=75	N=17	N=51	N=7
1. Do you have any preference in the schedule of ICI choice for the treatment of CPs?	□ Yes, I prefer the schedule with the shorter interval	31 (41.3)	9 (52.9)	21 (41.2)	1 (14.3)
	$\hfill\square$ Yes, I prefer the schedule with the longer interval	39 (52)	7 (41.2)	26 (51)	6 (85.7)
	□ No, the schedule interval is not a criteria for ICI choice in my clinical practice	5 (6.7)	1 (5.9)	4 (7.8)	0 (0)
2. Do you have currently (during COVID-19 pandemic) any preference in the schedule of ICIs for the treatment	$\hfill\square$ Yes, I prefer the schedule with the shorter interval	0 (0)	0 (0)	0 (0)	0 (0)
of CPs?	$\hfill\square$ Yes, I prefer the schedule with the longer interval	58 (77.3)	13 (76.5)	38 (74.5)	7 (100)
	$\hfill\square$ No, the schedule interval is not a criteria for ICI choice in my current clinical practice	17 (22.7)	2 (23.5)	13 (25.5)	0 (0)
3. Have you modified the dose of steroids you give in	$\hfill\square$ Yes, I have reduced the dose	3 (4)	1 (1.9)	1 (2)	1 (14.3)
case of ICI adverse events?	No, I continue to follow the recommendation for the AE management	72 (96)	16 (94.1)	50 (98)	6 (85.7)
4. Has the COVID-19 pandemic changed your treatment choice for CP-ICI in case of alternative treatments like chemotherapy, where applicable, as for clinical practice guidelines?	□ Yes	6 (8)	1 (5.9)	5 (9.8)	0 (0)
	🗆 No	69 (92)	16 (94.1)	46 (90.2)	7 (100)
5. Has the COVID-19 pandemic changed your treatment	□ Yes	9 (12)	2 (11.8)	6 (11.8)	1 (14.3)
choice for CP-ICI in case of alternative treatments like targeted therapy, where applicable, as for clinical practice guidelines?	🗆 No	66 (88)	15 (88.2)	45 (88.2)	6 (85.7)
6. Are the CP-ICI preferentially seen in COVID-19 clear	□ Yes	29 (38.7)	6 (35.3)	21 (41.2)	2 (28.6)
institutions?	□ No	46 (61.3)	11 (64.7)	30 (58.8)	5 (71.4)
7. Do you use G-CSF in case of CP-ICIs with no febrile	□ Yes	12 (16)	1 (5.9)	11 (21.6)	0 (0)
neutropenia (when used ±chemotherapy)?	□ No	63 (84)	16 (94.1)	40 (78.4)	7 (100)
8. Has this decision been changed by the COVID-19	□ Yes	6 (8)	2 (11.8)	4 (7.8)	0 (0)
pandemic?	□ No	69 (92)	15 (88.2)	47 (92.2)	7 (100)
9. Have the CP-ICI been managed in expert centers for	□ Yes	53 (70.7)	15 (88.2)	34 (66.7)	4 (57.1)
immunotherapy?	□ No	22 (29.3)	2 (11.8)	17 (33.3)	3 (42.9)
10. Has this decision been changed by the COVID-19	□ Yes	1 (1.3)	0 (0)	1 (2)	0 (0)
pandemic?	□ No	74 (98.7)	17 (100)	50 (98)	7 (100)
11. Do you prefer to delay ICI start in lung cancer	□ Yes	8 (10.7)	3 (17.6)	4 (7.8)	1 (10.7)
patients because of potential lung toxicity considering the high lung tropism of SARS-CoV-2 virus and its risk of ARDS?	🗆 No	67 (89.3)	14 (82.4)	47 (92.2)	6 (85.7)
12. In your institution, has surgery for CP been delayed	□ Yes	35 (46.7)	9 (52.9)	24 (47.1)	2 (28.6)
because of the COVID-19 pandemic?	□No	40 (53.3)	8 (47.1)	27 (52.9)	5 (71.4)

H CPR: high (H) prevalence regions with more than 10,000 positive patients, M CPR: medium (M) prevalence regions with positive patients less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 4000 positive patients.

ARDS, acute respiratory distress syndrome; CP, cancer patient; CP-ICI, cancer patients undergoing or candidate for immune checkpoint inhibitor; ICI, immune checkpoint inhibitor; N, number.

SARS-CoV-2 before starting adjuvant ICIs, while only 5.9%, 11.8% and 28.6% from H, M and L CPR delayed ICI start independently of the COVID-19 screening. Intriguingly, for metastatic CPs, there was nearly unanimous consent on the use of screening test for COVID-19, avoiding ICI start delays (H=94.1%, M=90.2%, L=100%). None of the L CPR physicians had any of the CPs treated with ICIs positive for SARS-CoV-2, while 29.4% and 31.4% of the H and M CPR had less than 10 positive patients. The majority of these CPs were affected by thoracic cancers, followed by melanoma, and urogenital and breast cancers. Some differences emerged about the preference of ICI schedule interval. Routinely, 52.9%, 41.25%

and 14.3% of H, M and L CPR physicians would not use the schedule interval as a criterion of choice for ICI treatment; however, an ICI with a longer schedule interval was preferable for 41.2%, 51% and 85.7% of H, M and L CPR responders. Despite these differences, there was high consensus on the preference of longer ICI schedule interval during the COVID-19 pandemic (H=76.5%, M=74.5%, L=100%), with none of the participants opting for a shorter ICI schedule interval. There was also a large consensus about not modifying the recommended steroid dose in case of immune-related adverse events (ir-AEs) (H=94.1%, M=98%, L=85.7%). Moreover, the majority of physicians did not change the ICI indication in favor

Table 5 Answers to multiple choice questions of survey section 1 for Campania region					
		All, n (%)	CC, n (%)	UH, n (%)	GH, n (%)
Questions	Multiple-choice responses	N=38	N=10	N=12	N=16
1. How do you triage your (CP-ICI) patients for SARS-CoV-2?	\square By telephone the day before the appointment	7 (18.4)	1 (10)	2 (16.7)	4 (25)
	Outside the hospital the same day of the clinic appointment	6 (15.8)	4 (40)	0 (0)	2 (12.5)
	 By telephone the day before the appointment and outside the clinic the day of the appointment 	25 (65.8)	5 (50)	10 (83.3)	10 (62.5)
2. Who among CP-ICI patients do you preferentially use telemedicine?	Patients in follow-up after finishing ICI adjuvant treatment	2 (5.3)	0 (0)	0 (0)	2 (12.5)
	□ Patients in follow-up who achieve complete response	1 (2.6)	0 (0)	0 (0)	1 (6.3)
	□ Both	30 (78.9)	8 (80)	12 (100)	10 (62.5)
	None of the above, I am not using telemedicine	5 (13.2)	2 (20)	0 (0)	3 (18.8)
3. How do you manage the new patients with	□ Delay ICI start for COVID-19 in all patients	0 (0)	0	0	0
cancer who need to start ICIs for metastatic disease?	□ Triage screening for COVID-19 risk factors	34 (89.5)	8 (80)	12 (100)	14 (87.5)
	□ Both	2 (5.3)	1 (10)	0 (0)	1 (6.3)
	□ None of the above	2 (5.3)	1 (10)	0 (0)	1 (6.3)
4. How do you manage the new patients with	Delay ICI start for COVID-19 in all patients	1 (2.6)	1 (10)	0 (0)	0 (0)
cancer who need to start ICIs for adjuvant	□ Triage screening for COVID-19 risk factors	29 (76.3)	8 (80)	8 (66.7)	13 (81.3)
purpose?	□ Both	5 (13.2)	1 (10)	4 (33.3)	0 (0)
	□ None of the above	3 (7.9)	0 (0)	0 (0)	3 (18.8)
5. Do you have any CP-ICI who tested positive to	□ Yes	12 (31.6)	5 (50)	6 (50)	1 (6.3)
SARS-CoV-2?	□ No	26 (68.4)	5 (50)	6 (50)	15 (93.8)
6. If yes, how many?	□<10	12 (100)	5 (100)	6 (100)	1 (100)
	□ 10–20	0 (0)	0 (0)	0 (0)	0 (0)
	□ 20–50	0 (0)	0 (0)	0 (0)	0 (0)
	□ 50–100	0 (0)	0 (0)	0 (0)	0 (0)
7. If yes, the most frequent CP-ICI SARS-CoV-2	Uro-genital cancers	3 (25)	1 (20)	0 (0)	0 (0)
positive are affected by?	Thoracic cancers	5 (41.7)	0 (0)	6 (100)	1 (100)
		4 (33.3)	4 (80)	0 (0)	0 (0)
	 Head and neck cancers 	0 (0)	0 (0)	0 (0)	0 (0)
	□ Other	0 (0)	0 (0)	0 (0)	0 (0)
8. How do you manage CP-ICI showing suspicious symptoms for COVID-19? (more than	1. Order the SARS-CoV-2 test and continue with the ICIs avoiding delays	2 (5.3)	2 (20)	0 (0)	0 (0)
1 option allowed)	2. Suspend the ICIs while waiting for the test results	15 (39.5)	6 (60)	5 (41.7)	4 (25)
	3. Ask for Rx thorax even in the absence of severe respiratory symptoms	0 (0)	0 (0)	0 (0)	0 (0)
	4. Ask for thorax CT scan even in the absence of severe respiratory symptoms	1 (2.6)	0 (0)	0 (0)	1 (6.3)
	5. Ask for blood test including: CBC, lactate dehydrogenase, high-sensitivity C reactive protein, interleukin-6, D-dimer	0 (0)	0 (0)	0 (0)	0 (0)
	6. 2+5	2 (5.3)	0 (0)	0 (0)	2 (12.5)
	7.2+3	2 (5.3)	0 (0)	0 (0)	2 (12.5)
	8. 2+3+5	4 (10.5)	0 (0)	4 (33.3)	0 (0)
	9. 2+3+4	1 (2.6)	0 (0)	0 (0)	1 (6.3)
	10. 2+4	4 (10.5)	1 (10)	2 (16.7)	1 (6.3)
	11. 2+4+5	7 (18.4)	1 (10)	1 (8.3)	5 (31.3)

CBC, complete blood count; CC, cancer center; CP, cancer patient; CP-ICI, cancer patients undergoing or candidate for immune checkpoint inhibitor; GH, general hospital; ICI, immune checkpoint inhibitor; N, number; UH, university hospital.

... .

. .

...

~

		All, n (%)	CC, n (%)	UH, n (%)	GH, n (%)
Questions	Multiple-choice responses	N=38	N=10	N=12	N=16
1. Do you have any preference in the schedule of ICI choice for the treatment of CPs?	□ Yes, I prefer the schedule with the shorter interval	4 (10.5)	0 (0)	3 (25)	1 (6.3)
	Yes, I prefer the schedule with the longer interval	18 (47.4)	6 (60)	5 (41.7)	7 (43.8)
	$\hfill\square$ No, the schedule interval is not a criteria for ICI choice in my clinical practice	16 (42.1)	4 (40)	4 (33.3)	8 (50)
2. Do you have currently (during COVID-19 pandemic) any preference in the schedule of	Yes, I prefer the schedule with the shorter interval	0 (0)	0 (0)	0 (0)	0 (0)
ICIs for the treatment of CPs?	Yes, I prefer the schedule with the longer interval	28 (73.7)	7 (70)	8 (66.7)	13 (81.3)
	□ No, the schedule interval is not a criteria for ICI choice in my current clinical practice	10 (26.3)	3 (30)	4 (33.3)	3 (18.8)
3. Have you modified the dose of steroids you	Yes, I have reduced the dose	1 (2.6)	0 (0)	0 (0)	1 (6.3)
give in case of ICI adverse events?	□ No, I continue to follow the recommendation for the AE management	37 (97.4)	10 (100)	12 (100)	15 (93.8)
4. Has the COVID-19 pandemic changed	□ Yes	4 (10.5)	0 (0)	2 (16.7)	2 (12.5)
your treatment choice for CP-ICI in case of alternative treatments like chemotherapy, where applicable, as for clinical practice guidelines?	□ No	34 (89.5)	10 (100)	10 (83.3)	14 (87.5)
5. Has the COVID-19 pandemic changed	□ Yes	6 (15.8)	2 (20)	4 (33.3)	0 (0)
your treatment choice for CP-ICI in case of alternative treatments like targeted therapy, where applicable, as for clinical practice guidelines?	🗆 No	32 (84.2)	8 (80)	8 (66.7)	16 (100)
6. Are the CP-ICI preferentially seen in	□ Yes	14 (36.8)	2 (20)	7 (58.3)	5 (31.3)
COVID-19 clear institutions?	□ No	24 (63.2)	8 (80)	5 (41.7)	11 (68.8)
7. Do you use G-CSF in case of CP-ICIs	□ Yes	9 (23.7)	3 (30)	4 (33.3)	2 (12.5)
with no febrile neutropenia (when used ±chemotherapy)?	□ No	29 (76.3)	7 (70)	8 (66.7)	14 (87.5)
8. Has this decision been changed by the	□ Yes	4 (10.5)	1 (10)	1 (8.3)	2 (12.5)
COVID-19 pandemic?	□ No	34 (89.5)	9 (90)	11 (91.7)	14 (87.5)
9. Have the CP-ICI been managed in expert	□ Yes	26 (68.4)	8 (80)	10 (83.3)	8 (50)
centers for immunotherapy?	□ No	12 (31.6)	2 (20)	2 (16.7)	8 (50)
10. Has this decision been changed by the	□ Yes	1 (2.6)	0 (0)	0 (0)	1 (6.3)
COVID-19 pandemic?	□ No	37 (97.4)	10 (100)	12 (100)	15 (93.8)
11. Do you prefer to delay ICI start in lung cancer patients because of potential lung toxicity considering the high lung tropism of SARS-CoV-2 virus and its risk of ARDS?	□ Yes	2 (5.3)	0 (0)	2 (16.7)	0 (0)
	□ No	36 (94.7)	10 (100)	10 (83.3)	16 (100)
12. In your institution, has surgery for CP been	□ Yes	16 (42.1)	1 (10)	9 (75)	6 (37.5)
delayed because of the COVID-19 pandemic?	□ No	22 (57.9)	9 (90)	3 (25)	10 (62.5)

~ ~

ARDS, acute respiratory distress syndrome; CC, cancer center; CP, cancer patient; CP-ICI, cancer patients undergoing or candidate for immune checkpoint inhibitor; G-CSF, granulocyte colony stimulating factor; GH, general hospital; ICI, immune checkpoint inhibitor; N, number; UH, university hospital.

of alternative treatments such as chemotherapy when applicable (H=94.1%, M=90.2%, L=100%), or targeted therapy (H=88.2%, M=88.2%, L=85.7%), relatively to solid tumors with actionable target such as renal cancer, hepatocarcinoma and melanoma, where targeted therapy may be used as an alternative to ICI choice regardless of the COVID-19 pandemic, as for clinical practice

guidelines. In terms of supportive treatments, there was a large agreement in using the G-CSF only in cases of febrile neutropenia during the COVID-19 pandemic (H=88.2%, M=92.2%, L=100%), as well as indicated during the standard clinical practice, for both clinical situation of immunotherapy alone or immunotherapy plus chemotherapy. CPs treated with ICIs were looked after in centers with

immunotherapy expertise in most cases (H=88.2%, M=66.7%, L=51.1%), and this strategy was not affected by the COVID-19 pandemic (H=100%, M=98%, L=100%). Furthermore, the majority of the physicians did not delay ICI start in lung CPs, although considering the potential lung toxicity related to these agents and despite the high lung tropism of SARS-CoV-2 virus and its risk of acute respiratory distress syndrome (ARDS). On the other hand, delay in surgical treatment was reported by 52.9% of the H CPR doctors, 47.1% of the M CPR doctors and 28.6% of the L CPR doctors. These differences were, however, not statistically significant.

Focus on the Campania region (M CPR) experience: differences and similarities among CC, UH and GH

Most of the results are comparable with the national ones. The majority of Campanian doctors assessed CPs for COVID-19 symptoms by telephone consultation on the day before and on the day of clinic appointment through physical examinations in dedicated areas (CC=60%, UH=83.3%, GH=62.5%). High consensus about ICI interruptions in case of suspected COVID-19 CPs was registered, with only 5.3% of physicians declaring to continue ongoing ICIs without delays. Moreover, 60%, 41.7% and 25% of responders (respectively from CC, UH and GH) did not perform any additional diagnostic examinations. As national results, the most favorite diagnostic work-up, where required, included ICI interruption, thorax CT scan and blood tests, as previously described (CC=10%, UH=8.3%, GH=31.3%). Telemedicine was broadly used for both patients in follow-up after completing ICI adjuvant treatment or achieving complete response (CC=80%, UH=100%, GH=62.5%). Screening test for COVID-19 was adopted for CPs candidate for adjuvant ICIs (CC=80%, UH=66.7%, GH=81.3%), as well as for metastatic patients (CC=80%, UH=100%, GH=87.5%), therefore avoiding ICI start delays. Several physicians had CPs positive for SARS-CoV-2 (less than 10) while on treatment with ICIs (CC=50%, UH=50%, GH=6.3%; p=0.017). Routinely, 40%, 33.3% and 50%, of CC, UH and GH doctors, respectively, would not use the schedule interval as criterion of choice for ICI treatment. Of note, none of the CC doctors gave preference for shorter interval schedules. However, as for national results, an ICI with a longer schedule interval was the favorite option for 70%, 66.7% and 81.3% of CC, UH and GH responders, respectively, during the COVID-19 pandemic. There was also almost unanimous consensus on not modifying the recommended steroid dose in case of ir-AEs (CC=100%, UH=100%, GH=93.8%). The majority of doctors did not change ICIs in favor of chemotherapy (CC=100%, UH=83.3%, GH=87.5%), as well as in favor of targeted therapy, when applicable (CC=80%, UH=66.7%, GH=100%); this last result was statistically different (p=0.05). In terms of supportive treatment, there was agreement for using the G-CSF only in cases of febrile neutropenia (CC=70%, UH=87.5%, GH=66.7%), with no substantial changes during the COVID-19 pandemic. Almost unanimous agreement was

detected on not delaying ICI start in lung CPs (CC=100%, UH=83.3%, GH=100%). Finally, a statistically significant difference was found in surgical treatment delays among different contexts (CC=10%, UH=75%, GH=37.5%; p=0.008).

DISCUSSION

Young Italian oncologists' experience: ensuring high quality of care in the midst of the COVID-19 pandemic

The WHO research agency (IARC) estimated 18.1 million new cancer cases with 9.6 million cancer deaths in 2018.¹⁰ As of May 8, 2020, over 3.0 million cases of COVID-19 and more than 250,000 related deaths have been reported¹: these numbers tell the unrestrainable progression of two shocking illnesses affecting humans with reciprocal implications.¹¹ While cancer is a long-lasting health challenge for thousands of physicians and entire health systems worldwide, COVID-19 has overwhelmed the healthcare system rapidly and with unprecedented virulence; therefore, the sum of both diseases can have devastating outcomes. As a result, medical oncologists are facing a very hard time during the COVID-19 pandemic, shacked among reassessing standards of cancer care, adapting day-by-day healthcare system and acknowledging the paradoxical need to keep patients away from the healthcare facilities and minimize the admissions. Several recommendations from cancer societies and expert opinions have been promptly developed to guide and to find practical solutions for the oncology clinic daily practice.¹² However, despite the prospering number of recent publications on this topic,^{6 8 10} there is still a great deal of uncertainty about COVID-19 and its effects on CPs. A recent meta-analysis of 11 studies revealed that the overall pooled prevalence of CPs with COVID-19 was 2.0%, with higher risk of severe events such as increased percentage of CPs admitted to intensive care unit who required invasive ventilation, or died, as compared with non-oncologic patients.¹³ Recently, the experience on COVID-19 and cancer from an oncology hub institution in Milan has been reported; of note, only two out of nine COVID-19positive CPs presented with severe illness receiving in-patient care, and none of the two patients receiving immunotherapy experienced severe adverse outcomes.¹⁴ These data provide preliminary insights into the correlation between COVID-19 and cancer; however, data regarding COVID-19 impact on CPs undergoing ICIs are still lacking and the big deal of postponing or changing treatments or treatment schedule without compromising their efficacy, especially for ICI high responsive malignancies such as melanoma and lung cancer, is a matter of great interest in the oncological community. Our study represents the first snapshot of the measures adopted by young Italian medical oncologists to ensure the best quality treatment to CPs without jeopardizing the success of ICIs. From our study, we can conclude that, while the COVID-19 hurricane has prompted the re-organization of the healthcare structures, called to re-adapt all their areas to ensure physical distancing and protection with specific equipment, the management strategies for CPs treated with immunotherapy have largely remained intact among different centers and regions that participated to our survey. Indeed, there was an almost unanimous consent of not delaying immunotherapy in the adjuvant setting as well as for metastatic disease, and at the same time trying to adopt cautionary measures such as triage screening for COVID-19, reduction of the number of in-person accesses to clinic by preferring, when possible, ICIs with longer interval schedule and broad use of telemedicine for patients in follow-up after ICIs. It is of note that there is an almost unanimous consent to screen for COVID-19 symptoms in metastatic patients, therefore avoiding immunotherapy delays. This highlights the inclination of protecting a more fragile category at higher risk of cancer progression and related complications in case of delay of systemic treatment and the general confidence of the young oncological community in the efficacy and safety of immunotherapy. In the same way, the majority of physicians preferred ICIs over the use of chemotherapy or targeted therapy. This large agreement most likely reflects the priority to ensure a high level of oncological assistance for CPs as also suggested by the preferential management in expertise centers for immunotherapy. Interestingly, there was also a large consensus about not modifying the recommended steroid dose in case of ir-AEs. Although emerging reports¹⁵¹⁶ and previous reviews of outcomes in other viral pneumonias^{17 18} showed that corticosteroids' action, to decrease the host inflammatory responses in the lungs, may be overshadowed by adverse effects, such as delayed viral clearance and increased risk of secondary infection, no randomized clinical trials have clearly demonstrated the harms and lack of proven benefit for steroid use in patients with COVID-19. Conversely, the benefit of steroid administration for ir-AE management has been widely proven.¹⁹ As a result, the majority of responders feel confident to not modify steroid dose in case of ir-AEs.

Finally, the discrepancy about the COVID-19 screening modality before the appointment in the clinic, with only telephone check on the day before for the L CPR, may be related only to the low positive cases registered in that region. COVID-19 clean areas do not reflect the majority of responders in Italy since different hospital contexts were included in the survey.

Campania experience: ensuring high-quality care maintaining medium COVID-19 prevalence in the first Italian region for population density

The National Institute of Health reports each year in Campania (comprising Naples, the third largest city in Italy, and the provincial capitals of Salerno, Caserta, Avellino and Benevento) 398 new cases of cancer per 100,000 inhabitants for the male sex versus a national rate of 336 per 100,000 inhabitants.^{20 21} Of note, Campania is the third most populous Italian region (after Lombardia and Lazio) with over 5.8 million residents within 13,671

km² and the first for population density with 1499 inhabitants per square kilometer.²² As a consequence, during the Italian COVID-19 emergency, the Campania Region Health Committee has pursued the great challenge to control the virus spread in such a high-risk territory, trying to maintain high-quality level of assistance and to protect the most fragile populations, including the oncological one. Basically, considering the pre-existing hub-andspoke scheme of Rete Oncologica Campana (ROC Oncology Network of Campania Region), founded with the Regional Act n°98 in 2016,²³ for ensuring equity of access to the local oncological users, and for integrating regional health facilities,²⁴ during COVID-19 time, Campania Region restructured the service delivery by maintaining the ROC network-based model and re-adapting some existing health structures as COVID-19 preferential hubs. Recently, also a dedicated COVID-19 center for SARS-CoV-2-positive CPs was assembled at Ospedale del Mare, in Naples. With the support of territorial medicine, based on primary healthcare, and the large use of telemedicine, the challenging aim to contain the COVID-19 infection, while maintaining essential healthcare, seems to have been achieved. Indeed, Campania remains as a medium COVID-19 prevalence region, with few positive cases among CPs reported so far. All the multidisciplinary referral oncological centers (CORP), identified by the ROC and included in our survey, have promptly re-organized the clinical daily practice with triage screening procedures in line with the national directions. Regarding the issue of CPs treated with immunotherapy, addressed specifically by our survey, the Campanian results are very similar to the national ones, highlighting the big effort of all the oncological communities to deliver high standard care also during emergency period. Few responses were statistically different among CC, UH and GH. Very intriguingly, GH, which are included in the ROC with equal volume of CPs compared with UH and CC, had the lowest rate of positive CPs treated with ICIs, probably due to the faster activation of COVID-19 clean areas. Of note, there was also a higher percentage of Campanian oncologists who consider targeted therapy in place of ICIs, maybe due to the higher number of physicians committed to melanoma cancer enrolled in the subanalysis for Campania region.

CONCLUSIONS

Despite the limited number of responders and the lack of participants from some Italian regions, the results of our study highlight, for the first time, the common efforts of Italian young oncologists, who are daily involved in the management of CPs treated with ICIs, in maintaining high standard treatments during the COVID-19 pandemic. As the oncology community is daily facing the evolving COVID-19 global health emergency and trying to fill the gap of scientific and clinic data, it is imperative that clinical practice data-driven decisions are shared by those caring for patients.

RECOMMENDATIONS

We have summarized the viewpoint of the responders to this survey in a brief list of recommendations that we believe would be of help for CP management with ICIs during the COVID-19 pandemic. This is not a formally developed guideline, but rather reflects the opinion of a robust number of Italian oncologists daily involved in delivering immunotherapy in CPs.

- CPs treated with ICIs should be preferentially assessed for COVID-19–related symptoms by telephone consultation on the day before the hospital appointment and on the day of clinic appointment through physical examinations in dedicated areas.
- Telemedicine should be applied to both CPs who achieved complete response after ICI treatment and patients who finished ICI treatment with adjuvant purpose.
- Triage screening for COVID-19 should be performed for both patients with metastatic disease and patients who are starting immunotherapy in adjuvant setting, avoiding any delays.
- When applicable, the clinicians should adopt the longest schedule of ICIs to reduce the monthly hospital admissions.
- ICIs should be withheld until an active SARS-CoV-2 infection has resolved or has been ruled out with highly accurate molecular testing, as per international guidelines.
- ► In case of adverse events, the physicians should follow the current recommendation for ICI-related adverse event management according to toxicity grade, without reducing the dose of steroids.
- ► In case of non-febrile neutropenia, physicians should not prescribe G-CSF, as per clinical practice.
- CPs treated with ICIs should be referred preferentially to immunotherapy expertise centers.
- ► ICIs in patients with lung cancer should not be avoided for fear of potential lung toxicity and given the high lung tropism of SARS-CoV-2 virus and its risk of ARDS in asymptomatic and/or coronavirus-free patients.

Author affiliations

¹Oncology Unit, Ospedale del Mare, Napoli, Campania, Italy

²Department of Clinical Medicine and Surgery, Università degli Studi di Napoli Federico II and CRCTR Coordinating Rare Tumors Reference Center of Campania Region, AOU Federico II, Napoli, Italy

³Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy

⁴Clinical Studies, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK

⁵CRCTR Coordinating Rare Tumors Reference Center of Campania Region, AOU Federico II, Napoli, Campania, Italy

⁶Biostatistics Unit, IRCCS Regina Elena National Cancer Institute, Roma, Lazio, Italy ⁷Medical Oncology Unit, Department of Onco-Hematology, IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Basilicata, Italy

⁸Oncology Unit, Ospedale Ferdinando Veneziale, Isernia, Molise, Italy
⁹Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS

Fondazione Pascale, Napoli, Campania, Italy

¹⁰Abdominal Oncology Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy

¹¹Medical Oncology Unit, University of Pisa, Pisa, Toscana, Italy

¹²Oncology Unit, Ospedale del Mare, Napoli, Italy

¹³Department of Radioterapia, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy

¹⁴Oncology Unit, San Rocco Hospital, Sessa Aurunca, Campania, Italy
¹⁵Oncology Unit, Ospedale Della Murgia, Bari, Puglia, Italy

¹⁶U.O.C. Oncologia, Azienda Ospedaliera dei Colli, Monaldi Hospital, Napoli, Campania, Italy

¹⁷Department of Medical Oncology, AORN "A. Cardarelli", Napoli, Campania, Italy ¹⁸Oncology Unit, Villa Scassi Hospital, Genova, Italy

¹⁹Oncology, Department of Precision Medicine, Università della Campania "L. Vanvitelli", Napoli, Campania, Italy

²⁰Medical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Emilia-Romagna, Italy

²¹Oncology Unit, Sant'Ottone Frangipane Hospital, Avellino, Campania, Italy

²²Oncology Unit, Sant'Anna e San Sebastiano, Caserta, Campania, Italy

²³Breast Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy

²⁴Department of Clinical Medicine and Surgery, Oncology Unit, Università degli Studi di Napoli Federico II, Napoli, Campania, Italy

²⁵Oncology Unit, Gemelli Molise s.p.a, Campobasso, Molise, Italy

²⁶Division of Medical Oncology, "San Giuseppe Moscati" Hospital, Avellino, Campania, Italy

²⁷Oncology Unit, SS Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Piemonte, Italy

²⁸Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy

²⁹Department of Oncology, University of Verona, Verona, Veneto, Italy

³⁰Department of Medical Oncology, Santa Chiara Hospital, Trento, Trentino Alto Adige, Italy

³¹UOC Oncologia Medica, Ospedali Riuniti Villa Sofia Cervello, Palermo, Sicilia, Italy
³²Department of Oncology, Azienda Sanitaria Universitaria Integrata del Friuli
Centrale, Udine, Friuli Venezia Giulia, Italy

³³Thoracic Medical Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy

³⁴Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada and British Columbia Cancer Agency—Vancouver Center—Department of Medicine, Division of Medical Oncology, University of British Columbia, Vancouver, British Columbia, Canada

³⁵Oncology Unit, Ospedale Sacro Cuore di Gesù Fatebenefratelli, Benevento, Campania, Italy

³⁶Institute of Research on Genetics and Biomedicine (IRGB), National Research Council (CNR), Sassari, Sardegna, Italy

³⁷Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", Oncology Unit, University of Salerno, Baronissi, Campania, Italy

³⁸U.O.C. Pneumologia Oncologica, Azienda Ospedaliera dei Colli, Monaldi Hospital, Naples, Campania, Italy

³⁹Veneto Institute of Oncology IOV-IRCCS, Padova, Veneto, Italy

⁴⁰Medical Oncology Unit, ASL CN2, Alba, Piemonte, Italy

⁴¹Medical Oncology Unit, Fondazione IRCCS Giovanni Paolo II, Bari, Puglia, Italy
⁴²Medical Oncology Unit, University Hospital Modena, Modena, Emilia Romagna, Italy

⁴³Oncology Unit, Fondazione Istituto San Raffaele G Giglio di Cefalu, Cefalu, Sicilia, Italy

⁴⁴Division of Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milano, Lombardia, Italy

⁴⁵Medical Oncology 1 Unit, IRCCS Regina Elena National Cancer Institute, Rome, Lazio, Italy

⁴⁶Oncology Division, ASL San Felice a Cancello, Caserta, Campania, Italy

⁴⁷Department of Surgery and Cancer, Imperial College, London, UK

⁴⁸Oncology Unit, Università degli Studi di Verona, sede Borgo Roma, Verona, Veneto, Italy

⁴⁹Medical Oncology Department, AOUI di Verona, Verona, Veneto, Italy

Contributors The authors listed below have made substantial contributions to the intellectual content of the paper in the various sections described below: conception and design: MO. Acquisition of data: MO, PR, MT, AP, AL, AA, FB, DB, BV, BG, CG, FC, CD, CA, CR, DFS, DFM, DPP, IDS, DSA, DFR, DLV, FA, PF, LF, PG, AMG, LM, MAL, MV, AM, MS, VM, CM, MM, MM, MAM, MB, PI, PS, AP, PL, PF, PE, PV, RV, MR, RA, RA, SM, SA, ES, ASi, SM, TarP, TavP, TF, TV, CT, VV, VS, VJ, MGV, FV, VC, ZF, ZI. Analysis and

Open access

interpretation of data: MO, PR. Drafting of the manuscript: MO, PR. Critical revision of the manuscript for important intellectual content: PG, BD, AZ, CvA, DT, LN, CMDC, FM, GC, NF, SG, PM, MG. Statistical analysis: DG, MO. Administrative, technical or material support: MT, MC. Supervision: PAA, SDP, FC, VM, FP, SP, DLM, VC, AM, GP, SP, MAM, MA, CG.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this survey report, formal consent is not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as online supplemental information. The submitting author will provide the data or will cooperate fully in obtaining and providing the data on which the manuscript is based for examination by the editors or their assignees.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Margaret Ottaviano http://orcid.org/0000-0001-9589-0808 Valeria Merz http://orcid.org/0000-0002-2120-1923 Alessandro Morabito http://orcid.org/0000-0002-1319-9608 Angelica Petrillo http://orcid.org/0000-0001-5489-5733 Paolo Antonio Ascierto http://orcid.org/0000-0002-8322-475X

REFERENCES

- The World Health Organization (WHO). Coronavirus disease (COVID-19) pandemic. Available: https://www.who.int/emergencies/ diseases/novel-coronavirus-2019 [Accessed 8 May 2020].
- 2 The World Health Organization (WHO). Health emergency dashboard. Available: https://experience.arcgis.com/experience/ 685d0ace521648f8a5beeeee1b9125cd
- 3 Lazzerini M, Putoto G. COVID-19 in Italy: momentous decisions and many uncertainties. *Lancet Glob Health* 2020;8:e641–2.
- 4 Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.

- 5 Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21:335–7.
- 6 Desai A, Warner J, Kuderer N, et al. Crowdsourcing a crisis response for COVID-19 in oncology. Nat Cancer 2020;1:473–6.
- 7 Bersanelli M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. *Immunotherapy* 2020;12:269–73.
- 8 Ottaviano M, De Placido S, Ascierto PA. Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. *Virchows Arch* 2019;474:421–32.
- 9 Ascierto PA, Addeo R, Carteni G, et al. The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. J Transl Med 2014;12:291.
- 10 Lewis MA. Between Scylla and Charybdis oncologic decision making in the time of Covid-19. N Engl J Med 2020;382:2285–7.
- 11 Blandino G. Cancer at the time of the COVID-19 hurricane. J Exp Clin Cancer Res 2020;39:74.
- 12 Italian Ministry of Health. Recommendations for the management of hematology and oncology patients during the COVID-19 public health emergency. Available: http://www.trovanorme.salute.gov.it/ norme/renderNormsanPdf
- 13 Desai A, Sachdeva S, Parekh T, *et al.* COVID-19 and cancer: lessons from a pooled meta-analysis. *JCO Glob Oncol* 2020;6:557–9.
- 14 Trapani D, Marra A, Curigliano G. The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region. *Eur J Cancer* 2020;132:199–206.
- 15 Abid MB, Mughal M, Abid MA. Coronavirus disease 2019 (COVID-19) and immune-engaging cancer treatment. *JAMA Oncol* 2020. doi:10.1001/jamaoncol.2020.2367. [Epub ahead of print: 20 May 2020].
- 16 Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. *Lancet* 2020;395:473–5.
- 17 Wong SSY, Yuen K-Y. The management of coronavirus infections with particular reference to SARS. J Antimicrob Chemother 2008;62:437–41.
- 18 Chihrin S, Loutfy MR. Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome. *Expert Rev Anti Infect Ther* 2005;3:251–62.
- 19 Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2016;2:1346–53.
- 20 I numeri del cancro in Italia. AIOM 2019.
- 21 Fusco M, De Angelis R, Senatore G, et al. Estimates of cancer burden in Campania. *Tumori* 2013;99:374–81.
- 22 Annuario Statistico Italiano 2019. Available: https://www.istat.it/it/ files/2019/12/Asi-2019.pdf
- 23 2018 DECRETO N. 89 DEL 05.11.2018. BURC. Available: http://burc. regione.campania.it/eBurcWeb/directServlet?DOCUMENT
- 24 De Placido S, Bracale U, Pacelli R, et al. A new strategy for a high tumour burden region: the Campania oncological network. Transl Med UniSa 2020;21:59–60.